Patient-factors associated with metformin steady-state levels in type 2 diabetes mellitus with therapeutic dosage

ConclusionsAlong with initial hyperglycemia and eGFR, metformin Cssmin became the only parameter that influenced FBG level (P < 0.05). Duration of previous metformin use should be considered in the strategy of optimizing metformin dosage. The type-2 diabetes patients with obesity are more suggested to take shorter interval of metformin administration (or possibly with sustained-release formulation) to keep Cssmin within the therapeutic range.
Source: Journal of Clinical and Translational Endocrinology - Category: Endocrinology Source Type: research